Talk Presenting Companies (Theatre A) track
Oncology: Pin Therapeutics
Mon, Nov 9, 2026 · 2:30–2:45 PM CET Koelnmesse
About this session
Pin Therapeutics is a clinical stage TPD (Targeted Protein Degradation) company dedicated to developing novel E3 ligases and molecular glue degraders for the treatment of solid tumors and hematologic cancers. Our lead program, PIN-5018, a first-in-class CK1α-selective molecular glue degrader, is currently in a Phase 1a clinical study in Korea and is being developed for adenoid cystic carcinoma (ACC), castration-resistant prostate cancer (CRPC), and colorectal cancer (CRC).
Speaker
-
Founder & CEO · Pin Therapeutics
Speaker